Literature DB >> 27964794

The role of the gastrointestinal tract in the pathogenesis of rheumatic diseases.

Francesco Ciccia1, Angelo Ferrante2, Giuliana Guggino2, Giovanni Triolo2.   

Abstract

Dysregulation of the intestinal epithelial barrier in genetically susceptible individuals may lead to both intestinal and extraintestinal autoimmune disorders. There is emerging literature on the role of microbiota changes in the pathogenesis of systemic rheumatic diseases such as rheumatoid arthritis, spondyloarthropathies, and connective tissue diseases. Although the role of the gastrointestinal tract in the pathogenesis of spondyloartropathies is well defined and many studies underline the importance of gastrointestinal inflammation in modulating local and systemic inflammation, the data are inconclusive regarding the effect of dysbiosis on rheumatoid arthritis and connective tissue diseases. This review aims to summarize current data on the role of the gastrointestinal involvement and intestinal microbiota in the pathogenesis of systemic rheumatic disease.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Connective tissue diseases; Dysbiosis; Gastrointestinal tract; Rheumatoid arthritis; Spondyloarthropathy

Mesh：

Year:  2016        PMID： 27964794     DOI： 10.1016/j.berh.2016.10.003

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN： 1521-6942            Impact factor:   4.098


  7 in total

Review 1.  Gastrointestinal and Hepatic Disease in Rheumatoid Arthritis.

Authors:  Ethan Craig; Laura C Cappelli
Journal:  Rheum Dis Clin North Am       Date:  2018-02       Impact factor: 2.670

Review 2.  Intestinal dysbiosis and probiotic applications in autoimmune diseases.

Authors:  Gislane Lelis Vilela de Oliveira; Aline Zazeri Leite; Bruna Stevanato Higuchi; Marina Ignácio Gonzaga; Vânia Sammartino Mariano
Journal:  Immunology       Date:  2017-06-29       Impact factor: 7.397

3.  Efficacy and safety of faecal microbiota transplantation in patients with psoriatic arthritis: protocol for a 6-month, double-blind, randomised, placebo-controlled trial.

Authors:  Maja Skov Kragsnaes; Jens Kjeldsen; Hans Christian Horn; Heidi Lausten Munk; Finn Moeller Pedersen; Hanne Marie Holt; Jens Kristian Pedersen; Dorte Kinggaard Holm; Henning Glerup; Vibeke Andersen; Ulrich Fredberg; Karsten Kristiansen; Robin Christensen; Torkell Ellingsen
Journal:  BMJ Open       Date:  2018-04-27       Impact factor: 2.692

4.  Analysis of Gut Microbiota in Rheumatoid Arthritis Patients: Disease-Related Dysbiosis and Modifications Induced by Etanercept.

Authors:  Andrea Picchianti-Diamanti; Concetta Panebianco; Simonetta Salemi; Maria Laura Sorgi; Roberta Di Rosa; Alessandro Tropea; Mayla Sgrulletti; Gerardo Salerno; Fulvia Terracciano; Raffaele D'Amelio; Bruno Laganà; Valerio Pazienza
Journal:  Int J Mol Sci       Date:  2018-09-27       Impact factor: 5.923

5.  The effect of probiotic cheese consumption on inflammatory and anti-inflammatory markers, disease severity, and symptoms in patients with rheumatoid arthritis: study protocol for a randomized, double-blind, placebo-controlled trial.

Authors:  Farzaneh Asoudeh; Kurosh Djafarian; Maassoumeh Akhalghi; Mahdi Mahmoudi; Ahmad Reza Jamshidi; Elham Farhadi; Ahmad Esmaillzadeh
Journal:  Trials       Date:  2022-02-24       Impact factor: 2.279

Review 6.  A review of JAK-STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition.

Authors:  Iain B McInnes; Zoltán Szekanecz; Dennis McGonagle; Walter P Maksymowych; Alexander Pfeil; Ralph Lippe; In-Ho Song; Apinya Lertratanakul; Thierry Sornasse; Ana Biljan; Atul Deodhar
Journal:  Rheumatology (Oxford)       Date:  2022-05-05       Impact factor: 7.046

7.  Bifidobacterium animalis ssp. Lactis 420 Mitigates Autoimmune Hepatitis Through Regulating Intestinal Barrier and Liver Immune Cells.

Authors:  Hongxia Zhang; Man Liu; Xin Liu; Weilong Zhong; Yanni Li; Ying Ran; Liping Guo; Xu Chen; Jingwen Zhao; Bangmao Wang; Lu Zhou
Journal:  Front Immunol       Date:  2020-10-06       Impact factor: 7.561
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.